Patrick Van Beneden

Partner, Health & Care at Gimv NV

Patrick Van Beneden

Patrick Van Beneden

Partner, Health & Care at Gimv NV

Overview
RelSci Relationships

843

Number of Boards

30

Birthday

1962

Age

57

Contact Data
Trying to get in touch with Patrick Van Beneden? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Patrick Van Beneden likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer & Director at Gimv NV

Relationship likelihood: Strong

Senior Scientist at Johnson & Johnson

Relationship likelihood: Strong

Managing Partner & Head-Sustainable Cities at Gimv NV

Relationship likelihood: Strong

Managing Partner & Head Connected Consumer at Gimv (Private Equity)

Relationship likelihood: Strong

Managing Partner & Head-Health & Care at Gimv (Private Equity)

Relationship likelihood: Strong

Chief Executive Officer at LMA BVBA

Relationship likelihood: Strong

Co-Founder at JenaValve Technology, Inc.

Relationship likelihood: Strong

Managing Partner & Head-Smart Industries at Gimv (Private Equity)

Relationship likelihood: Strong

Chief Financial Officer at Gimv NV

Relationship likelihood: Strong

Partner, Connected Consumer at Gimv NV

Relationship likelihood: Strong

Paths to Patrick Van Beneden
Potential Connections via
Relationship Science
You
Patrick Van Beneden
Partner, Health & Care at Gimv NV
Education

Hogeschool-Universiteit Brussel is a school in Brussels.

Career History
Partner
1985 - Current

Gimv-PE's investment focus is typically linked to unlisted firms requiring financing to accelerate growth, for corporate divestitures, for shareholders seeking liquidity and for family-owned firms with succession issues.The firm targets investments ranging from EUR 5-30 million. They seek equity participation through majority or significant minority stakes. They provide mezzanine finance for buy-outs and growth capital. When they provide MBO financing, they create a new shareholder structure taking a majority stake alone or with other private equity partners. In terms of growth capital provision, they take minority participations essentially leaving intact the firm's existing shareholder structure.Gimv-PE's investment criteria include mid-sized firms displaying robust market position or a holding niche position. They typically invest in firms with an enterprise value between EUR 20-125 million, in a wide range of sectors and with experienced management teams having proven performance records. They look for an alignment of interest among key partners. The firm does not invest in listed firms, start-ups or turnarounds.

Partner, Health & Care
Current

Gimv NV is an investment company that engages in private equity and venture capital activities. It operates through the following segments: Connected Consumer, Health & Care, Smart Industries, Sustainable Cities, and Other. The Connected Consumer segment comprises companies with a clear vision of the needs and preferences of the customer of the future. The Health & Care segment provides solutions for the health and care sector and caters to a growing, ageing, and health-conscious society. The Smart Industries segment supplies smart systems and services. The Sustainable Cities segment provides services, utilities, and infrastructure. The company was founded on February 25, 1980 and is headquartered in Antwerp, Belgium.

Boards & Committees
Director
2013 - Current

Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium.

Member, Board of Directors
Current

VitrOmics Healthcare Holding BV is a holding company, which engages in the development of new diagnostic products based on the PamChip technology platform. Its platform is used for academic and bio-pharmaceutical research applications. The company was founded by Tim Kievits and is headquartered in 's-Hertogenbosch, the Netherlands.

Director
Current

JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.

Transactions
Details Hidden

Intrexon Corp. purchases Intrexon Actobiotics NV from LSP Management Group BV, Ventech SA, Gimv (Private Equity), Aescap Venture Management BV, UGent TechTransfer

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Patrick Van Beneden. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Patrick Van Beneden's profile does not indicate a business or promotional relationship of any kind between RelSci and Patrick Van Beneden.